Laurus Labs Limited was originally incorporated as Laurus Labs Private Limited on September 19 2005 at Hyderabad Andhra Pradesh India as a private limited company. The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited on February 12 2007. Subsequently the name of the company was changed to Aptuit Laurus Limited consequent to the strategic partnership entered into by the company with Aptuit Singapore on July 19 2007. Thereafter the company was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited on July 24 2007. Subsequently the name of the company was changed to Laurus Labs Private Limited consequent to the proposed dilution of the shareholding of Aptuit Singapore in the Company on February 21 2012. Further the company was converted into a public limited company and the name of the company was changed to Laurus Labs Limited on August 16 2016.Laurus Labs is a leading research and development (R&D) driven pharmaceutical company in India with a leadership position in generic active pharmaceutical ingredients (APIs) for select high-growth therapeutic areas of anti-retrovirals (ARVs) and Hepatitis C. The company also manufactures APIs in oncology and other therapeutic areas. The company's strategic and early investments in R&D and manufacturing infrastructure has enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing donor-funded access-to-medicines markets of Sub-Saharan Africa South-East Asia and Latin America. The company also has growing synthesis and nutraceutical/cosmeceutical ingredients businesses. Further It is increasingly focused towards growing its integrated generics finished dosage forms (FDFs) business in which it has made significant investments.Laurus Labs operates in four business lines: Generics - APIs Generics - FDFs Synthesis and Ingredients. Its Generics - API business comprises the development manufacture and sale of APIs and advanced intermediates; itsGenerics - FDF business comprises the development and manufacture of oral solid formulations; its Synthesis business includes contract development and manufacturing services for global pharmaceutical companies; and its Ingredients business comprises the manufacture and sale of specialty ingredients for use in the nutraceutical and cosmeceutical sectors. The company has launched 59 products since its inception in 2005. Its key customers include Aspen Pharmacare Limited Aurobindo Pharma Limited Cipla Limited Mylan Laboratories Limited NATCO Pharma Limited (NATCO) and Strides Shasun Limited. As of September 30 2016 the Company owned 34 patents and had 152 pending patent applications in several countries.